^
Association details:
| Biomarker: | MAP2K1 P124L |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma
Excerpt:
Five MAP2K1 gene mutations (encodes the MEK1 kinase) were detected in either drug-resistance specimens (3 mutations; MEK1V60E, MEK1G128V, and MEK1V154I in Patients 41, 32, and 28, respectively) or pre-treatment tumors that progressed rapidly in the face of clinical RAF inhibition (2 mutations; MEK1P124S and MEK1P124L in Patients 4 and 15, respectively) (Fig. 1B).
DOI:
10.1158/2159-8290.CD-13-0617
